Crumly & Associates’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$213K Sell
4,991
-312
-6% -$16.9K 0.04% 187
2026
Q1
$333K Sell
5,303
-116
-2% -$9.28K 0.07% 144
2025
Q4
$517K Sell
5,419
-318
-6% -$31.2K 0.11% 107
2025
Q3
$560K Sell
5,737
-256
-4% -$26.5K 0.12% 101
2025
Q2
$644K Sell
5,993
-1,702
-22% -$172K 0.16% 81
2025
Q1
$776K Sell
7,695
-1,296
-14% -$131K 0.21% 68
2024
Q4
$803K Sell
8,991
-72
-0.8% -$6.34K 0.22% 68
2024
Q3
$759K Sell
9,063
-171
-2% -$13.5K 0.21% 71
2024
Q2
$711K Sell
9,234
-348
-4% -$25.5K 0.2% 68
2024
Q1
$656K Sell
9,582
-156
-2% -$10K 0.17% 76
2023
Q4
$563K Buy
9,738
+1,547
+19% +$82.6K 0.16% 79
2023
Q3
$432K Sell
8,191
-12
-0.1% -$629 0.17% 75
2023
Q2
$444K Buy
8,203
+2,695
+49% +$141K 0.18% 77
2023
Q1
$276K Buy
5,508
+31
+0.6% +$1.46K 0.12% 95
2022
Q4
$253K Buy
+5,477
New +$237K 0.1% 84

Other funds holding BSX

Crumly & Associates's BSX Position: Q2 2026 in Review

Crumly & Associates reduced its Boston Scientific (BSX) stake by 5.9% in Q2 2026, selling an estimated $16.9K and leaving 4,991 shares worth $213K. The position accounts for 0.04% of the portfolio, ranked #187.

Crumly & Associates first reported a position in BSX in Q4 2022 and has held it in 15 quarters since. The position peaked at $803K in Q4 2024. 303 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Crumly & Associates held 4,991 shares of Boston Scientific worth $213K as of Q2 2026.
  • Crumly & Associates sold 312 Boston Scientific shares in Q2 2026, an estimated $16.9K.
  • Boston Scientific made up 0.04% of Crumly & Associates's portfolio in Q2 2026, its #187 holding.
  • Crumly & Associates first reported a position in Boston Scientific in Q4 2022 and has held it in 15 quarters since.
  • Crumly & Associates's Boston Scientific position peaked at $803K in Q4 2024.
  • 303 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Crumly & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.